Date	e: 23/11 2022		
You	r name : Mathilde Fahren	ndorff	
Mar	nuscript title: Crystal Meth	amfetamin-induceret hyp	ertermi med fatal udgang
Mar	nuscript number (if known): UFL-10-22-0611	
are rethird comrist a The finance The aperta antih	elated to the content of yo parties whose interests manitment to transparency are relationship/activity/interest following questions apply to ascript only. Buthor's relationships/activities to the epidemiology of ypertensive medication, expanding to the content of the properties of the epidemiology of the second of the epidemiology of the epid	ur manuscript. "Related" in any be affected by the continued does not necessarily intest, it is preferable that you the author's relationship wities/interests should be given if that medication is not port for the work reported	declare all relationships with manufacturers of the manuscript. In this manuscript without time limit. For all
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time	e frame: Since the initial plan	,	
1	All support for the present	x None	
	manuscript (e.g., funding, provision of study		
	materials, medical writing,		
	article processing charges,		
	etc.)		
	No time limit for this		
	item.		
			Click TAB in last row to add extra rows
Time	o franco nast 2/ manths		onek wild in last few to dad oxid fews
TIM	e frame: past 36 months		
2	Grants or contracts from	x None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	x None	
	, and the second		

4	Consulting fees	x None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	x None	
6	Payment for expert testimony	x None	
7	Support for attending meetings and/or travel	x None	
8	Patents planned, issued or pending	x None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	x None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	x None	
11	Stock or stock options	x None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	x None	
13	Other financial or non-financial interests	x None	

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Date	e : 23/11 2022		
You	r name: Dorte Fris Palme	qvist	
Mar	nuscript title: Crystal Meth	amfetamin-induceret hyp	ertermi med fatal udgang
Mar	nuscript number (if known): UFL-10-22-0611	
In the are retained third committed the following the foll	e interest of transparency, elated to the content of yo parties whose interests manitment to transparency arrelationship/activity/interestionship questions apply to ascript only. Buthor's relationships/activities to the epidemiology of ypertensive medication, even	we ask you to disclose all a ur manuscript. "Related" a ay be affected by the continuous not necessarily intest, it is preferable that you the author's relationship of the author's relations	declare all relationships with manufacturers of the manuscript. In this manuscript without time limit. For all
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time	e frame: Since the initial plar	,	
1	All support for the present	x None	
	manuscript (e.g., funding, provision of study		
	materials, medical writing,		
	article processing charges, etc.)		
	,		
	No time limit for this item.		
	item.		
			Click TAB in last row to add extra rows
Time	e frame: past 36 months		
2	Grants or contracts from	x None	
۷	any entity (if not indicated	A NUITE	
	in item #1 above).		
3	Royalties or licenses	x None	
	,	7.140110	

4	Consulting fees	x None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	x None	
6	Payment for expert testimony	x None	
7	Support for attending meetings and/or travel	x None	
8	Patents planned, issued or pending	x None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	x None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	x None	
11	Stock or stock options	x None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	x None	
13	Other financial or non-financial interests	x None	

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Dat	e : 23/11 2022		
You	r name: Christian Aage	Wamberg	
Mai	nuscript title: Crystal Meth	amfetamin-induceret hyp	ertermi med fatal udgang
Maı	nuscript number (if known): UFL-10-22-0611	
In the are retained third comments and the first and the apertained the interior and the interior and the apertained the interior and the apertained the apertained the apertained the interior and the apertained the aperta	e interest of transparency, elated to the content of yo parties whose interests manitment to transparency arrelationship/activity/interestionship questions apply to ascript only. Buthor's relationships/activities to the epidemiology of ypertensive medication, even	we ask you to disclose all a ur manuscript. "Related" a ay be affected by the continuous not necessarily intest, it is preferable that you the author's relationship of the author's relations	declare all relationships with manufacturers of the manuscript. In this manuscript without time limit. For all
otnei	items, the time name for	disclosure is the past 50 f	IIUITUIS.
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Tim	e frame: Since the initial plar	,	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	x None	
	No time limit for this item.		
			Click TAB in last row to add extra rows
Time	e frame: past 36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	x None	
3	Royalties or licenses	x None	

4	Consulting fees	x None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	x None	
6	Payment for expert testimony	x None	
7	Support for attending meetings and/or travel	x None	
8	Patents planned, issued or pending	x None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	x None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	x None	
11	Stock or stock options	x None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	x None	
13	Other financial or non-financial interests	x None	

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

	Date: Klik eller tryk for at an			
Y	our name: SARA		NTH HINDKJER	
			ETAMIN-INDICERET	HYPERIERMI M
٨	Manuscript number (if know	wn):		(100)
a ti o li:	re related to the content of hird parties whose interests commitment to transparencests of a relationship/activity/in	s may be affected by the or y and does not necessaril terest, it is preferable tha	e all relationships/activities/intered" means any relation with for-peontent of the manuscript. Discloy indicate a bias. If you are in do t you do so.	sure represents a ubt about whether to
TI	ne following questions approached anuscript only.			t SANOTA - An Traille - An
ar	tihypertensive medication,	, even if that medication is	uld declare all relationships with s not mentioned in the manuscripted in this manuscript without tin 6 months.	λ.
	4	Name all entities with	Specifications/Comments	
4		whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to y institution)	ou or to your
in	ne frame: Since the initial plan	nning of the work		
	All support for the present	None None		
pi	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges,			
	etc.)	i		
		1		
	No time limit for this			
_	item.	1	Click TAB in last r	ow to add extra rows
	ne frame: past 36 months	3		
in		. 71		
	Grants or contracts from	⊠ None		
	Grants or contracts from any entity (if not indicated	⊠ None		
	네트 보다 가는 아이에 보는 맛을 살아 하면 하는 것이 없었다. 그렇게 되었다. 그렇	⊠ None		
	any entity (if not indicated in item #1 above).	7		
ila !	any entity (if not indicated	⊠ None		

4	Consulting fees	☑ None
_		
5	Payment or honoraria for lectures, presentations,	M None ■
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	 None
	testimony	
7	Support for attending	⊠ None
	meetings and/or travel	
		-A
8	Patents planned, issued or	Ŋ None
	pending	
_		
9	Participation on a Data	⊠-None **
	Safety Monitoring Board or Advisory Board	
	of Advisory Board	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	M None
11	Stock or stock options	☑ None
		78
		.79
12	Receipt of equipment,	⊠None
	materials, drugs, medical	
	writing, gifts or other services	
_		⊠ None
13	Other financial or non- financial interests	None (i)
-	illianciai interests	

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal
Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish
Medical Journal.

e : 23/11 2022		
r name: Signe Tellerup N	Nielsen	
nuscript title : Crystal Meth	amfetamin-induceret hyp	ertermi med fatal udgang
nuscript number (if known): UFL-10-22-0611	
elated to the content of yo parties whose interests maitment to transparency at relationship/activity/interest following questions apply truscript only. Buthor's relationships/activities to the epidemiology of the sypertensive medication, even #1 below, report all support and the particular support and the sypertensive medication, even #1 below, report all support and support support and support support and support support support support support support support suppor	ur manuscript. "Related" in any be affected by the continuous not necessarily intest, it is preferable that you the author's relationship wities/interests should be given if that medication is not port for the work reported	means any relation with for-profit or not-for-profit ent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to u do so. Disclosive represents as they relate to the current defined broadly. For example, if your manuscript declare all relationships with manufacturers of the manuscript. If in this manuscript without time limit. For all
	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
e frame: Since the initial plar		
All support for the present	x None	
materials, medical writing,		
article processing charges,		
etc.)		
No time limit for this		
item.		
		Click TAB in last row to add extra rows
e frame: past 36 months		
Grants or contracts from	x None	
пп цетт # г ароvе).		
Royalties or licenses	x None	
	nuscript title: Crystal Methonscript number (if known e interest of transparency, elated to the content of yo parties whose interests maitment to transparency at relationship/activity/interestionship/activity/interestionship/activity/interestionship/activity/interestionships/ac	nuscript title: Crystal Methamfetamin-induceret hypenuscript number (if known): UFL-10-22-0611 e interest of transparency, we ask you to disclose all elated to the content of your manuscript. "Related" parties whose interests may be affected by the content mitment to transparency and does not necessarily increlationship/activity/interest, it is preferable that yo following questions apply to the author's relationshipuscript only. author's relationships/activities/interests should be gains to the epidemiology of hypertension, you should hypertensive medication, even if that medication is not mean and the following provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Value Value

4	Consulting fees	x None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	x None	
6	Payment for expert testimony	x None	
7	Support for attending meetings and/or travel	x None	
8	Patents planned, issued or pending	x None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	x None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	x None	
11	Stock or stock options	x None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	x None	
13	Other financial or non-financial interests	x None	

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal